enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Update

enVVeno Medical Corporation (NASDAQ:NVNO) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 447,400 shares, a decrease of 16.0% from the February 28th total of 532,700 shares. Currently, 2.6% of the company’s stock are sold short. Based on an average daily trading volume, of 127,600 shares, the short-interest ratio is presently 3.5 days.

enVVeno Medical Price Performance

NASDAQ:NVNO traded down $0.11 during midday trading on Tuesday, hitting $2.52. The company’s stock had a trading volume of 78,706 shares, compared to its average volume of 107,480. The firm has a market cap of $44.19 million, a P/E ratio of -1.96 and a beta of 1.38. The firm’s 50 day moving average is $3.17 and its 200-day moving average is $3.31. enVVeno Medical has a fifty-two week low of $2.45 and a fifty-two week high of $6.48.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. As a group, analysts forecast that enVVeno Medical will post -1.32 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NVNO. Jane Street Group LLC acquired a new stake in enVVeno Medical in the 4th quarter valued at approximately $56,000. Northern Trust Corp boosted its position in enVVeno Medical by 68.3% during the fourth quarter. Northern Trust Corp now owns 56,725 shares of the company’s stock valued at $171,000 after purchasing an additional 23,029 shares during the last quarter. Altium Capital Management LLC increased its position in enVVeno Medical by 29.8% during the fourth quarter. Altium Capital Management LLC now owns 310,000 shares of the company’s stock worth $936,000 after buying an additional 71,080 shares during the last quarter. Marshall Wace LLP bought a new position in shares of enVVeno Medical in the fourth quarter valued at approximately $147,000. Finally, Geode Capital Management LLC grew its holdings in enVVeno Medical by 20.6% in the 4th quarter. Geode Capital Management LLC now owns 181,737 shares of the company’s stock valued at $549,000 after buying an additional 31,061 shares during the last quarter. Institutional investors and hedge funds own 34.71% of the company’s stock.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).